PRINCETON, N.J., April 30 -- Combining prostate cancer images with dual-modality imaging, or fusion imaging, can help detect the location and extent of prostate cancer, said researchers at University Hospitals of Cleveland, Case Western Reserve University, who will present findings at the American Urological Association's annual meeting today in Chicago. The researchers will discuss their studies of 400 prostate cancer patients whose treatment was significantly modified by fused ProstaScint and CT imaging, said D. Bruce Sodee, M.D., professor of radiology at the university.
ProstaScint, an antibody-based imaging agent used to reveal the extent and spread of prostate cancer, is manufactured by Cytogen Corp., a biopharmaceutical company that focuses on oncology.
"The studies illustrate that ProstaScint fusion imaging and optimization can be used to guide both surgery and radiation therapy in addition to following the progress of patients' disease," said Martin I. Resnick, M.D., chief of urology at Case Western and president-elect of the American Urological Association.
For more information, visit: www.cytogen.com